Lexeo appoints CDO, CMO, Senior Advisor, and Chief Business & Legal Officer

Lexeo Therapeutics, Inc.

Sandi See Tai promoted to Chief Development Officer; previously VP at Pfizer, led tafamidis ATTR-ACT program.
Eric Adler appointed Chief Medical Officer & Head of Research; former CSO at Lexeo, UCSD professor, gene therapy pioneer.
Rajiv Patni named Senior Advisor to CEO & Board; former CRO at Reata (acquired by Biogen), led Skyclarys approval.
Jenny Robertson promoted to Chief Business and Legal Officer; previously Chief Legal & Admin Officer, Pfizer rare disease counsel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.